Links

©Viva Biotech (Shanghai) Ltd. 沪ICP备12042930号   Powerd by 300.cn 

Viva Biotech and Shanghai Biomedical Fund Announce the Cooperation to Jointly Build the Medical Innovation Achievement Transformation Platform

Classification:
News
Author:
Viva
Source:
Viva
2020/12/22 13:13
[Abstract]:
Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D.
SHANGHAI, CHINA ------ In Dec. 16th, 2020, the Shanghai Biomedical Industry Equity Investment Fund (hereinafter referred to as "Shanghai Biomedical Fund"), which is approved by the Shanghai Municipal Government and initiated by Shanghai Industrial Investment Holdings was launched in Shanghai. Viva Biotech attended the ceremony and signed the cooperation agreement, to jointly build the Shanghai Biomedical Innovation Achievement Transformation Platform.
 
Viva Biotech will give full play to its capabilities and advantages as a one-stop comprehensive service platform for drug R&D, actively cooperate with transformation platforms, and provide all-round medical R&D support including but not limited to CRO/CDMO/CMO services, investment incubation services, site and equipment for continuous development of scientific research results